BACKGROUND AND PURPOSE: Atrial natriuretic peptide (ANP) stimulates lipolysis in human adipocyte through a cGMP signalling pathway, the regulation of which is poorly known. Since phosphodiesterases (PDE) and neutral endopeptidase (NEP) play a major role in the regulation of the biological effects of natriuretic peptides in the cardiovascular and renal systems, we investigated whether these mechanisms could regulate cGMP signalling and ANP-mediated lipolysis in human adipocytes. EXPERIMENTAL APPROACH: The presence of cGMP-specific PDE and NEP in differentiated pre-adipocytes and in mature adipocytes was evaluated by real-time qPCR and Western blot. The effect of non-selective and selective inhibition of these enzymes on ANP-mediated cGMP signalling and lipolysis was determined in isolated mature adipocytes. KEY RESULTS: PDE-5A was expressed in both pre-adipocytes and adipocytes. PDE-5A mRNA and protein levels decreased as pre-adipocytes differentiated (10 days). PDE-5A is rapidly activated in response to ANP stimulation and lowers intracellular cGMP levels. Its selective inhibition by sildenafil partly prevented the decline in cGMP levels. However, no changes in baseline- and ANP-mediated lipolysis were observed under PDE-5 blockade using various inhibitors. In addition, NEP mRNA and protein levels gradually increased during the time-course of pre-adipocyte differentiation. Thiorphan, a selective NEP inhibitor, completely abolished NEP activity in human adipocyte membranes but did not modify ANP-mediated lipolysis. CONCLUSIONS AND IMPLICATIONS: Functional PDE-5A and NEP activities were present in human adipocytes, however these enzymes did not play a major role in the regulation of ANP-mediated lipolysis.
BACKGROUND AND PURPOSE:Atrial natriuretic peptide (ANP) stimulates lipolysis in human adipocyte through a cGMP signalling pathway, the regulation of which is poorly known. Since phosphodiesterases (PDE) and neutral endopeptidase (NEP) play a major role in the regulation of the biological effects of natriuretic peptides in the cardiovascular and renal systems, we investigated whether these mechanisms could regulate cGMP signalling and ANP-mediated lipolysis in human adipocytes. EXPERIMENTAL APPROACH: The presence of cGMP-specific PDE and NEP in differentiated pre-adipocytes and in mature adipocytes was evaluated by real-time qPCR and Western blot. The effect of non-selective and selective inhibition of these enzymes on ANP-mediated cGMP signalling and lipolysis was determined in isolated mature adipocytes. KEY RESULTS:PDE-5A was expressed in both pre-adipocytes and adipocytes. PDE-5A mRNA and protein levels decreased as pre-adipocytes differentiated (10 days). PDE-5A is rapidly activated in response to ANP stimulation and lowers intracellular cGMP levels. Its selective inhibition by sildenafil partly prevented the decline in cGMP levels. However, no changes in baseline- and ANP-mediated lipolysis were observed under PDE-5 blockade using various inhibitors. In addition, NEP mRNA and protein levels gradually increased during the time-course of pre-adipocyte differentiation. Thiorphan, a selective NEP inhibitor, completely abolished NEP activity in human adipocyte membranes but did not modify ANP-mediated lipolysis. CONCLUSIONS AND IMPLICATIONS: Functional PDE-5A and NEP activities were present in human adipocytes, however these enzymes did not play a major role in the regulation of ANP-mediated lipolysis.
Authors: Cédric Moro; Jan Polak; Jindra Hejnova; Eva Klimcakova; François Crampes; Vladimir Stich; Max Lafontan; Michel Berlan Journal: Am J Physiol Endocrinol Metab Date: 2005-11-15 Impact factor: 4.310
Authors: Cédric Moro; Jan Polak; Blanka Richterova; Coralie Sengenès; Terezie Pelikanova; Jean Galitzky; Vladimir Stich; Max Lafontan; Michel Berlan Journal: Metabolism Date: 2005-01 Impact factor: 8.694
Authors: K Loughney; T R Hill; V A Florio; L Uher; G J Rosman; S L Wolda; B A Jones; M L Howard; L M McAllister-Lucas; W K Sonnenburg; S H Francis; J D Corbin; J A Beavo; K Ferguson Journal: Gene Date: 1998-08-17 Impact factor: 3.688
Authors: N Yanaka; J Kotera; A Ohtsuka; H Akatsuka; Y Imai; H Michibata; K Fujishige; E Kawai; S Takebayashi; K Okumura; K Omori Journal: Eur J Biochem Date: 1998-07-15
Authors: L De Toni; G Strapazzon; L Gianesello; N Caretta; C Pilon; A Bruttocao; C Foresta Journal: J Endocrinol Invest Date: 2011-11 Impact factor: 4.256
Authors: M Rydén; J Bäckdahl; P Petrus; A Thorell; H Gao; M Coue; D Langin; C Moro; P Arner Journal: Int J Obes (Lond) Date: 2015-10-26 Impact factor: 5.095
Authors: K F Standeven; K Hess; A M Carter; G I Rice; P A Cordell; A J Balmforth; B Lu; D J Scott; A J Turner; N M Hooper; P J Grant Journal: Int J Obes (Lond) Date: 2010-11-02 Impact factor: 5.095
Authors: Linda S Hoffmann; Jennifer Etzrodt; Lena Willkomm; Abhishek Sanyal; Ludger Scheja; Alexander W C Fischer; Johannes-Peter Stasch; Wilhelm Bloch; Andreas Friebe; Joerg Heeren; Alexander Pfeifer Journal: Nat Commun Date: 2015-05-26 Impact factor: 14.919